Sucampo Pharmaceuticals Культура компании

Dr. Peter A. Kiener, Ph.D., has been the Chief Science Officer at Sucampo Pharmaceuticals, Inc. since October 27, 2014. Dr. Kiener serves as the Chief Scientific Officer and Head of R&D at Sucampo Pharma Americas LLC. He has deep experience in both biologics and immunotherapy. Dr. Kiener was a Co-Founder of Zyngenia, Inc. and served as its President from 2009 to 2013. Prior to joining Sucampo, Dr. Kiener served as Chief Scientific Officer of Ambrx, Inc. since August 2013. Prior to Ambrx, Dr. Kiener served as Chief Executive Officer and President of Zyngenia, Inc. and leads business and drug development efforts. He served as an Executive Vice President of Research at MedImmune Inc. since February 2008 and its Head of research and development. Dr. Kiener worked on biologics for BristolMyers Squibb from 1983 to 2001. He was worked at MedImmune LLC from 2001 to 2009. His scientific areas of expertise include immunology, cellular and molecular biology, biochemistry and high-throughput screening assays and in vivo studies. He served as Dean's Advisory Board at the University of Maryland. He also held leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President of Research since February 2008 and Global Head of Biologics Research and Development, Senior Vice President of Research since February 2005 and Head of Global Research and Vice President of Research since September 8, 2003. Dr. Kiener has made expert and strategic contributions in supervising MedImmune's rapidly expanding product portfolio, particularly in the areas of cancer and inflammatory disease research as well as translational sciences. Since 2001. Dr. Kiener worked for 18 years at Pharmaceutical Research Division at Bristol Myers Squibb (BMS). He serves as the Chairman at Cue Biopharma, Inc. He serves as Chairman of Board of Managers at Resolve Therapeutics LLC. He serves as Director at TetraGenetics, Inc. He serves as Member of Scientific Advisory Board at Siamab Therapeutics, Inc. He has been a Member of Scientific Advisory Board at Genocea Biosciences, Inc., since November 23, 2009. He serves as a Member of the Scientific Advisory Board at NKT Therapeutics, Inc. and Genocea. He has been a Director of Cue Biopharma, Inc. since March 2016. He served as a Director of Zyngenia, Inc. He served as a Director and Board Observer of Virdante Pharmaceuticals Inc. He served as a Director of Immunology, Inflammation and Pulmonary Drug Discovery. He served as a Member of the Scientific Advisory Board at KAI Pharmaceuticals, Inc. He served as a Member of the Scientific Advisory Board at VLST Corporation. He served as a Research Associate at the Department of Biochemistry, University of Massachusetts (Amherst) and as a Postdoctoral Research Assistant of Medical Research Council, Sir William Dunn School of Pathology, University of Oxford. He served as Director of Synovex Inc. He served as a Director of Receptor BioLogix, Inc. He served as an Assistant Professor at the University of North Texas/Texas College of Osteopathic Medicine's Department of Anatomy. Dr. Kiener has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. He has authored or co-authored 78 scientific publications. Dr. Kiener received a Doctor of Philosophy Degree in Biochemistry from University of Oxford and a Bachelor of Science Degree in Chemistry from Lancaster University.

Ms. Elissa Cote has been Senior Vice President of Global Strategic Marketing & Alliance Management at Sucampo Pharmaceuticals, Inc. since October 10, 2016. Ms. Cote is responsible for managing Sucampo's business partners as part of Sucampo's Global Alliance Agreements to market and sell Sucampo's lead product, AMITIZA and supports all commercial planning and global strategic marketing responsibilities for the organization both for commercial-stage and pipeline-stage opportunities. She joined Sucampo in April 2014. She served as Vice President of Marketing and External Relations at Histogenics Corporation since September 2013 until April 01, 2015. She served as Director of Global Strategic Marketing, Emerging Brands for MedImmune, LLC, the biologics division of AstraZeneca PLC from June 2009 to July 2013. From March 2007 to June 2009, Ms. Cote served as a Strategic Management Consultant at The North Highland Company. From September 1996 to March 2007, Ms. Cote served as a Strategic Management Consultant at Accenture LLP. Ms. Cote has a B.A. in Political Science from Union College.

Ms. Misako Nakata, R.Ph. served as an Executive Vice President and Chief Intellectual Property Officer of Sucampo Pharma, LLC. Ms. Nakata served as the Chief Intellectual Property Officer and Executive Vice President of Sucampo Pharmaceuticals, Inc. from November 2008 to October 2016. She has a long career in strategic intellectual property planning and execution including prostones, for more than 10 years, which has led to the successful prosecution of more than 500 patents worldwide. She also has been involved in various research projects and licensing for Sucampo. She served as a Representative Director at Sucampo Pharma Ltd. since June 2004. Ms. Nakata holds a Pharmacist license.

Mr. Gregory A. Deener, also known as Greg has been Senior Vice President of Global Marketing & Strategy Implementation at Sucampo Pharmaceuticals, Inc. since March 2012. Mr. Deener serves as Senior Vice President of Global Marketing, Strategy & Implementation at Sucampo Pharma Americas, Inc. and served as its Vice President of Marketing, Strategy & Implementation. Mr. Deener served as Vice President of Marketing & Sales of GTX Inc., since January 20, 2005. Mr. Deener has over 20 years of experience in the design and execution of sales and marketing for several successful products and has launched a urology medicine within the U.S. He served as Vice President of Product Commercialization at GTX Inc., since January 20, 2005. He served as Director of Marketing and Sales of GTX, Inc., from February 11, 2004 to January 20, 2005. In this position, he was responsible for the strategic design and implementation of marketing and sales strategies for GTx, Inc. From 1996 to December 2003, Mr. Deener served as a Marketing Director for GlaxoSmithKline in various roles within the U.S. and Europe. Most recently, Mr. Deener was responsible for the launch of Avodart, a urology medicine for BPH. From 1983 to 1996, Mr. Deener served for Procter & Gamble in Brand Management and Sales. Mr. Deener holds a B.S. in Business Administration from the University of North Carolina at Chapel Hill.

Dr. Jones W. Bryan, also known as Woody, Ph.D. has been Senior Vice President of Business Development and Licensing at Sucampo Pharmaceuticals, Inc. since April 10, 2017 and served as its Senior Vice President of Business Development since April 10, 2017 until April 10, 2017. Dr. Bryan served as Vice President of Business Development at Supernus Pharmaceuticals, Inc. from 2005 to April 9, 2015. Dr. Bryan served as a Vice President of Project Management at Supernus Pharmaceuticals, Inc. In 1991, Dr. Bryan joined the pharmaceutical industry and served as a Senior Scientist of Schering Plough and then worked in Business Development at AAI from 1993 to 2000, where he served as its Global Product Director for Pharmaceutics. He joined Shire in January 2000. Prior to joining Sucampo, he served as Senior Vice President BD of Lupin Inc., where he was responsible for business development for the brand division, since 2015. From 2005 to 2015, Dr. Bryan was Vice President Business Development of Supernus Pharmaceuticals Inc., a development and commercial stage CNS specialty company. Dr. Bryan's responsibilities at Shire included business development, licensing and Project Management for Shire's bioavailability enhancement and oral controlled release drug delivery technologies as well as Management Team member. He serves as a Member of Advisory Board at Capital A Partners. Dr. Bryan serves as an Advisory Board Member to IIR's Drug Delivery Partnerships Conference. Dr. Bryan serves on the Board of Directors of Afecta Pharmaceuticals. Dr. Bryan received a Ph.D. degree in Pharmaceutics from the Medical University of South Carolina in 1991, B.S. in Zoology from Clemson University.

Mr. Jason Patrick Meyenburg has been Chief Commercial Officer Sucampo Pharmaceuticals, Inc. since April 2017. Mr. Meyenburg served as Chief Commercial Officer at Vtesse, Inc. since January 4, 2017. Mr. Meyenburg's primary responsibilities at Vtesse center on leading commercialization activities for the company. He served as Senior Vice President of Commercial Operations for The Americas at Alexion Pharmaceuticals, Inc. At Alexion, he led operations in the U.S. and Latin America including responsibility across the company's hematology, nephrology and metabolic disorder businesses. He held commercial roles of increasing responsibility at Alexion, expanding access to the company's products in new markets, including Europe, the Middle East, Africa and Japan. He has extensive experience in the launch of therapies for ultra-rare diseases including direction of new market entry, organizational development and market access. He holds a Bachelor of Science in Biochemistry from the University of Maryland and a Master's of Business Administration from Duke University's Fuqua School of Business.

Dr. Peter Lichtlen, M.D., Ph.D., B.B.A. serves as Chief Medical Officer of Numab Therapeutics AG. Dr. Lichtlen is the co-founder of Numab Therapeutics AG. Dr. Lichtlen has been the Chief Medical Officer of Sucampo Pharmaceuticals, Inc. since July 2014 and served as its Vice President of European Operations and Senior Medical Officer at Sucampo Pharmaceuticals, Inc. from June 2011 to September 14, 2013. He served as Vice President of European Operations and Senior Medical officer at Sucampo AG since July 14, 2011. Dr. Lichtlen served as Head of Clinical Research & Development and Medical Director of ESBATech AG since 2001, where he led several preclinical development projects with antibody fragments in oncology, inflammatory and neurodegenerative diseases. He developed ESBATech's 'body compartment concept' aimed at the optimal therapeutic exploitation of the pharmacokinetic properties of antibody fragments. He designed and led clinical development programs in ophthalmology and rheumatology with ESBA105 and ESBA1008, TNF-inhbitory and VEGF-inhibitory antibody fragments, respectively. He joined ESBATech as a Scientist in December 2000, working on the establishment of new platform technologies. He served as Medical Applications Manager of ESBATech since January 2002. His scientific work was published in various medical and scientific journals. He held several progressively more senior positions, culminating in being named Medical Director/Head, Clinical R&D and a member of its senior management team, a position he held from October 2004 to December 2010. He serves as Member of Board of Advisors at Numab Therapeutics AG. He serves as a Member of the Scientific Advisory Board at Apidel SA. He is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP). He is the author or various peer-reviewed articles and holds four patents. His MD thesis was honoured by the University foundation council and he was selected for the MD/Ph.D. program by the Swiss Academy of Medical Sciences and the Swiss National Science Foundation (SNSF). Dr. Lichtlen studied Medicine at the University of Zurich, where he got his MD degree in 1996, characterising human embryonic diseases. He completed his Ph.D. degree in molecular biology in October 2000 at the Institute for Molecular Biology at the University of Zurich, working on gene regulation and cell stress.

Michael Massaro serves as the Vice President Clinical Operations of Sucampo Pharmaceuticals, Inc.. Michael started at Sucampo Pharmaceuticals, Inc. in April of 2017. Michael currently resides in Washington D.C. Metro Area.